

References

1. Adams, L., Chief of Special Projects Staff, Office of Legislative Affairs, Food and Drug Administration, Public Health Service, U.S. Department of Health and Human Services, **Rockville, MD**, letter to the Office of Technology Assessment, U.S. Congress, Washington, DC, Jan. 3, 1990.
2. Adamson, J., "The Promise of Recombinant Human erythropoietin," *Seminars in Hematology* **26(2) Supp. 2, 1989**.
3. **Albach, H.**, "Market Organization and Pricing Behavior of **Oligopolistic** Firms in the Ethical Drug Industry: An Essay in the Measurement of Effective Competition," *Kyklos* **32(3):523-40, 1979**.
4. Alter, H., "The Nation's Blood Supply: Is Absolute Safety Achievable?," abstract from a paper presented at a conference sponsored by the Department of Transfusion Medicine, National Institutes of Health, U.S. Department of Health and Human Services, Washington, DC, Nov. 1, 1989.
5. **Amgen, Inc.**, "Prescribing Information for **Epogen**", Thousand Oaks, CA, June 1989.
6. *Amgen Inc. vs. Chugai Pharmaceuticals Co. Ltd., and Genetics Institute, Inc.*, Civil Action 87-2617-Y, December 11, 1989.
7. Andrews, E.A., "Drug Ruling Is a Setback For Amgen," *New York Times*, pp. D1, D8, Mar. 15, 1990.
8. Arrow, K., "Uncertainty and the Welfare Economics of Medical Care," *American Economic Review*: **941-73**, December 1963.
9. Ayanian, R., "The Profit Rates and Economic Performance of Drug Rates," *Drug Development and Marketing*, **R.B. Helms** (ed.) (Washington, D.C.: American Enterprise Institute, 1975).
- 9a. Barton, W., Secretary, Department of Social and Rehabilitative Services, State of Kansas, "Statement," *Kansas Medicaid Prescription Drug Cost Reduction Program*, hearing before the Special Committee on Aging, Senate, U.S. Congress, Washington, DC, July 18, 1989.
10. Benson, J., Acting Commissioner Food and Drug Administration, Public Health Service, U.S. Department of Health and Human Services, "Statement," *The Orphan Drug Act, Drug Pricing, Competition and Reauthorization*, hearing before the Subcommittee on Health and the Environment, Committee on Energy and Commerce, House of Representatives, U.S. Congress, Washington, DC, Feb. 7, 1990.
11. Berger, E., Director of Government Relations and Regulatory Affairs, National Medical Care, **Waltham, MA**, personal communication, Nov. 13, 1989 and Dec. 15, 1989.
12. Berkow, P., (ed.), *The Merck Manual*, 15th Edition (**Rahway, NJ**: Merck and Company, 1987).
13. **Besarab, A., Vlases, P., Care, J.**, et al., "Subcutaneous (SC) Administration of Recombinant Human erythropoietin (**H-rEPO**) For Treatment of ESRD Anemia," *Kidney International: Abstracts* **37(1):236**, January 1990.
14. Black, H. (ed.), *Black's Law Dictionary*, 5th Edition (St. Paul, MN: West Publishing Co, **1979**).
15. Black, W., "Drug Products of Recombinant DNA Technology," *American Journal of Hospital Pharmacy* **46:1834-1844**, September 1989.
16. **Blagg, C.R.**, "Hemodialysis, Peritoneal Dialysis, and Related Therapies for Renal Dialysis and the Elderly/Technology," prepared for the U.S. Congress Office of Technology Assessment, 1986.
17. **Blagg, C. R.**, Director, Northwest Kidney Center, Seattle, WA, letter to the Office of Technology Assessment, U.S. Congress, Feb. 23, 1990.
18. **Blagg, C.R.** and Eschbach, J., Northwest Kidney Center, Seattle WA, letters to the Office of Technology Assessment, U.S. Congress, September 29, 1989 and February 9, 1990.
19. Bommer, J., **Ritz, E.**, Weinreich, T., et al. "Subcutaneous erythropoietin," *Lancet*, **2(8607):406, 1988**.
20. Booth, C., Director, Payment Policy, Health Care Financing Administration, U.S. Department of Health and Human Services, Baltimore, MD, personal communication, Feb. 23, 1990.

21. **Brenner, B.** and Lazarus, M. "Chronic Renal Failure: Pathophysiology and Clinical Considerations," *Harrison's Principles of Internal Medicine, 11th Edition*, R. Petersdorf, et al., (eds) (New York: McGraw Hill Book Co., 1987).
22. Brownlee, O. H., "Rates of Return to Investment in the Pharmaceutical Industry: A Survey and Critical Appraisal," *Issues in Pharmaceutical Economics*, R.A.Chien (cd.) (Lexington, MA: D.C. Heath and Company, 1979).
23. Bunn, H., "Hematologic Alterations: Anemia," *Harrison's Principles of Internal Medicine, 11th Edition*, R. Petersdorf, et al. (eds.) (New York: McGraw-Hill, 1987).
24. Burroughs Wellcome Co., "Retrovir Capsules, Retrovir Syrup," Patient Package Insert, Research Triangle Park, NC, March 1990.
25. **Buto, K.**, Director, Bureau of Payment Policy, Health Care Financing Administration, U.S. Department of Health and Human Services, Baltimore, MD, personal communication, July 18, 1989.
26. Canadian erythropoietin Study Group, "The Effect of Recombinant EPO upon Quality of Life and Functional Capacity of Anemic Patients on Chronic Hemodialysis," *Kidney International Abstracts, 1989*.
27. Carpenter, C., and Lazarus, M., "Dialysis and Transplantation in the Treatment of Renal Failure," *Harrison Principles of Internal Medicine, 11th Edition*, Petersdorf, R., et al. (eds.) (New York: McGraw Hill Book Co., 1987).
28. **Casati, S.**, Passerini, P., Campise, M., "Benefits and Risks of Protracted Treatment With Human Recombinant erythropoietin in Patients Having Hemodialysis," *British Medical Journal 295:1017-20,1987*.
29. **Chugai-Upjohn**, materials submitted to the Orphan Drug Products Group, Food and Drug Administration, U.S. Department of Health and Human Services, Rockville, MD, Nov. 14, 1989.
30. Clarkson, K.W., "The Use of Pharmaceutical Profitability Measures For Public Policy Actions," *Issues in Pharmaceutical Economics*, R.A.Chien (cd.) (Lexington, MA: D.C. Heath and Company, 1979).
31. Cocks, D. L., "Product Innovation and the Dynamic Elements of Competition in the Ethical Pharmaceutical Industry," *Drug Development and Marketing*, R.B. Helms (cd.) (Washington, DC: American Enterprise Institute, 1975).
32. Cocks, D.L., and Virts, J.R., "Pricing Behavior of the Ethical Pharmaceutical Industry," *The Journal of Business 47(3):349-362, 1974*.
33. Comanor, W. S., "The Political Economy of the Pharmaceutical Industry," *Journal of Economic Literature 24:1178-1217, 1986*.
34. Commerce Clearing House, Inc., "Physician Reimbursement, Entitlement to Part A Benefits," *Medicare and Medicaid Guide 1:745 (Chicago, IL: Commerce Clearing House, 1987)*.
35. Commerce Clearing House, Inc., *Medicare and Medicaid Guide* (Chicago, IL: Commerce Clearing House, Inc., 1989).
36. Costello, P., "The Tetracycline Conspiracy: Structure, Conduct, and Performance in the Drug Industry," *Antitrust Law and Economics*, Summer: pp. 13-44, 1968.
37. Creagh-Kirk, T., Doi, P., Andrews, E., et al., "Survival Experience Among Patients With AIDS Receiving Zidovudine," *Journal of the American Medical Association 260(20):3009-3015,1988*.
38. Curtis, J., Eastwood, J., Smith, E., et al., "Maintenance Hemodialysis," *Quarterly Medical Journal 38:49-89.1988*.
39. Dao, T. D., "Drug Innovation and Price Competition," *Managerial and Decision Economics 5(2):80-84, 1984*.
40. Davidson, R., Haley, N., Easterling, J., et al., "Serial Hemodynamic Changes Following Recombinant Human erythropoietin Therapy," *Kidney International 37:1,1990*.
41. **Degge Group, LTD**, *Estimating the Prevalence of Renal Failure in the U. S.*, report prepared for **Chugai-Upjohn**, Arlington, VA, December 1989.
42. Delano, B., Lundin, A., Quinn, R., et al., "Improvements in Quality of Life Following Treatment With Recombinant Human Erythropoietin In Anemia Hemodialysis Patients," *Amen-can Journal of Kidney Disease Abstracts 14(2) Supplement 1:14-18, 1989*.

43. Donald, L.L., Director of Operations, **Greenfield Health Services Corporation**, Birmingham, MI, personal communication, March 19,1990.
44. **Driscoll, D.**, Analyst, Office of Payment Policy, Health Care Financing Administration, Department of Health and Human Services, Baltimore, MD, personal communication, March 21,1990.
45. **Eggers, P.**, "Effect of Transplantation on the Medicare End-Stage Renal Disease Program," *New England Journal of Medicine* 318(4):223-229,1988.
46. **Eggers, P.**, "Projections of the End Stage Renal Disease Population to the Year 2000," *Proceedings of the Annual Public Health Conference on Records and Statistics*, National Center for Health Statistics, Public Health Service, U.S. Department of Health and Human Services, DHHS (PHS) 90-1214, pp. 121-126, (Baltimore, MD: November 1989).
47. **Eggers, P.**, Branch Chief, Office of Research and Demonstrations, Health Care Financing Administration, U.S. Department of Health and Human Services, Baltimore, MD, personal communication, Jan. 19, 1990 and April 9, 1990.
48. **Eisen, B.**, Chief Patent Counsel, Genetics Institute, Cambridge, MA, personal communication, March 28, 1990.
49. **Eschbach, J.**, "The **Anemia** of Chronic Renal Failure--Pathophysiology and Effects of Recombinant erythropoietin," *Kidney International* 35:134-48, 1989.
50. **Eschbach, J.**, Clinical Professor of Medicine, Division of Hematology, University of Washington Medical School, Seattle, WA, personal communication, Nov. 15, 1989; March 1990; April 4, 1990.
51. **Eschbach, J.**, as cited in M. **Haffner**, letter to the Office of Technology Assessment, U.S. Congress, **Washington, DC**, Jan. 9,1990.
52. **Eschbach, J.**, and **Adamson, J.**, "Correction of the Anemia of **Hemodialysis** Patients of Recombinant Human erythropoietin: Results of a **Multicenter** Study," *Kidney International Abstract* 33:189, 1988.
53. **Eschbach, J.**, and **Adamson, J.**, "**Recombinant erythropoietin: Implications for Nephrology**," *American Journal of Kidney Disease* 11:203-209, 1988.
54. **Eschbach, J.**, and **Adamson, J.**, "Guidelines for Recombinant erythropoietin Therapy," *American Journal of Kidney Disease* 15:2, Supplement 1,1989.
55. **Eschbach, J.**, and **Adamson, J.**, "The Pathophysiology and Treatment of the Anemia of Chronic Renal Failure," *Current Nephrology*, vol. 14, **H.C. Gonick** (ed.) (Chicago: **Mosby-Yearbook Medical Publishing**, forthcoming, 1990).
56. **Eschbach, J.**, **Abdulahadi, M.**, **Browne, J.**, et al., "Recombinant Human erythropoietin in Anemic Patients with End Stage Renal Disease: Results of a Phase 111 **Multicenter** Clinical Trial," *Annals of Internal Medicine* 111(12):992-1000, Dec. 15, 1989.
57. **Eschbach, J.**, **Egrie, J.**, **Downing, M.**, et al., "Correction of the Anemia of ESRD with Recombinant erythropoietin: Results of the Combined Phase I and II Clinical Trials," *New England Journal of Medicine* 316(2):73-78, 1987.
58. **Eschbach, J.**, **Kelly, M.**, **Haley, R.**, et al., "Treatment of the Anemia of Progressive Renal Failure with Recombinant erythropoietin," *New England Journal of Medicine* 321(3):158-163, July 20,1989.
59. **Evans, R.**, **Manninen, D.**, and **Garrison, L.**, "The **Quality of Life** of Patients with End Stage Renal Disease," *New England Journal of Medicine* 312(9): 553-559,1985.
60. **Evans R.**, **Rader, B.**, **Egrie, J.**, et al., "Correction of Anemia with Recombinant Human **Erythropoietin** Enhances the Quality of Life of **Hemodialysis** Patients: **Multicenter** erythropoietin Clinical Trial Study conducted at the University of Washington in Seattle," *American Society of Nephrology Abstract*, December 1989.
61. **Evans, R.**, **Rader, B.**, **Manninen, D.**, et al., "The **Quality of Life of Hemodialysis** Recipients Treated with Recombinant Human **Erythropoietin**," *Annals of Internal Medicine* 263(6):825-830,1990.
62. **Fratantoni, J.**, Director, Chief, Cellular Components Laboratory, Blood and Blood Products Division, Center on Drugs and **Biologics**, Food and Drug Administration, U.S. Department of Health and Human Services, Bethesda, MD, personal communication, July 21, 1989 and Apr. 2,1990.

63. Fried, W., "The Liver as a Source of Extrarenal erythropoietin," *W Blood* 40671-677, 1973.
64. **Gibilaro, S.**, Delano, S., Quinn, R., et al., "Improved Quality of Life When Receiving Recombinant Erythropoietin," *American Society of Nephrology Abstracts*, December 1989.
65. **Giblett, E.**, "Other Hematologic Disorders: Blood Groups and Blood Transfusions," *Harrison Principles of Internal Medicine*, 11th Edition, R. Petersdorf, et al. (eds.) (New York: McGraw Hill Book Co, 1987).
66. **Goodnough, L.**, Rudnick, S., Price, T., et al., "Increased Preoperative Collection of Autologous Blood with Recombinant Human Erythropoietin," *New England Journal of Medicine* 321(17):1163-1168, 1989.
67. **Gotch, F.**, and **Uehlinger, D.**, "Kinetic Modeling of the Individualized Epogen Prescription," unpublished paper submitted to *Kidney International*, 1990.
68. **Grimm, A.**, **Flaharty, K.**, **Hapkins, L.**, et al., "Economics of Epoetin Therapy," *Clinical Therapy* 8%07-11, 1989.
69. **Haffner, M.**, Director, Office of Orphan Products Development, Food and Drug Administration, U.S. Department of Health and Human Services, **Rockville, MD**, personal communication, Oct. 3, 1989 and Jan. 9, 1990.
70. **Hansen, R.**, "The Pharmaceutical Development Process: Estimates of Development Costs and Times and the Effect of Proposed Regulatory Changes," *Issues in Pharmaceutical Economics*, **R.A. Chien** (cd.) (Lexington, MA: D.C. Heath and Company, 1979).
71. **Hausman, L.**, Analyst, Congressional Budget Office, U.S. Congress, Washington, DC, personal communication, Jan. 18, 1990.
72. **Holland, P.**, and **Schmidt, P.**, *Standards for Blood Banks and Transfusion Services*, 12th edition (**Arlington, VA**: American Association of Blood Banks, 1987).
73. **Hornbrook, M.**, "Market Structure and Advertising in the U.S. Pharmaceutical Industry," *Medical Care* 16:90-109, February 1978.
74. **Hurwitz, M.A.**, and **Caves, R.E.**, "Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals," *Journal of Law and Economics* 31(2):299-320, October 1988.
75. Intergovernmental Health Policy Project, "Medicaid's Experience With End-Stage Renal Disease: Findings of a National Survey," *Focus On...* 28, November 1989.
76. **Jacobsen, L.**, **Goldwasser, E.**, **Fried, W.**, et al., "The Role of the Kidney in Erythropoiesis," *Nature* 179:633, 1957.
77. **Jeffrey, P.**, Director of Pharmacy, University of Maryland Hospitals and Clinics, Baltimore, MD, personal communication, March 20, 1990.
78. **Joglekar, P.**, and **Patterson, M. L.**, "A Closer Look at the Returns and Risks of Pharmaceutical R& D," *Journal of Health Economics* 5(2):153-77, 1986.
79. **Johnson, C.A.**, "Acute and Chronic Renal Failure," *Applied Therapeutics: the Clinical Use of Dregs*, **L.Y. Young** and **M.A. Koda-Kimble** (eds.) (Vancouver, WA: Applied Therapeutics, Inc., 1988).
80. **Johnson, C.**, and **Chester, M.**, "Pathophysiology and Treatment of the Anemia of Renal Failure," *Clinical Pharmacy* 7:117-122, 1988.
81. Journal of the American Medical Association, "From the Health Care Financing Administration," *Journal of the American Medical Association* 262(3):328, 1989.
82. **Kelly, M.**, **Haley, N.**, **Adamson, J.**, et al., "How Subcutaneous Recombinant Human Erythropoietin Is as Effective and Safe as Given Intravenously," *American Society of Nephrology Abstracts*, December 1989.
83. **Kleinman, K.**, **Schweitzer, S.**, **Perdue, C.**, et al., "The Use of Recombinant Human Erythropoietin in the Correction of Anemia in Predialysis Patients and Its Effects on Renal Function: A Double Blind Placebo Controlled Trial," *American Society of Nephrology Abstracts*, 1988.
84. **Knapp, D.**, "Paying for Outpatient Prescription Drugs and Related Services in Third-Party Programs," *Medical Care Review* 28:826-59, 1971.
85. **Kramer, G.**, Audit Manager, Office of the Inspector General, U.S. Department of Health and Human Services, Baltimore, MD, personal communication, March 1990.
86. **Kuhn, K.**, **Nonnast-Daniel, B.**, **Grutzmacher, P.**, et al., "Analysis of Initial Resistance to Erythropoiesis to Treatment With Recombinant Human

- erythropoietin," *Contributions to Nephrology* 66:94-103, 1988.
87. **Lancet**, "Anemia in Premature Infants," *Lancet* 2(8572):1371, 1987.
 88. **Leffler, K.B.**, "Persuasion or Information? Economies of Prescription Drug Advertising," *Journal of Law and Economics*: 45-74, April 1981.
 89. **Leibowitz, A.**, Manning, W., and Newhouse, J., "The Demand for Prescription Drugs as a Function of Cost-Sharing," *Social Science and Medicine* 21(10):1063-69, 1985.
 90. **Levin, N.W.**, President, Renal Physicians Association, Washington, DC, personal communication, March 19, 1990.
 91. **Levinsky, N.**, "Fluids and Electrolytes," *Harrison's Principles of Internal Medicine*, 11th Edition, R. Petersdorf, et al. (eds.) (New York: McGraw Hill Book Co., 1987).
 92. **Lim, V.**, DeGowin, R., **Zavala, D.**, et al., "Recombinant Human erythropoietin Treatment in Predialysis Patients," *Annals of Internal Medicine* 110(2):108-114, 1989.
 93. **Longstreet, D.**, President, Biotechnology Division, Ortho Pharmaceutical Co., Raritan, NJ, personal communication, October 13, 1989.
 94. **Mannimen, D.**, Research Scientist, **Battelle Memorial Institute**, Seattle, WA, personal communication, March 15, 1990 and March 19, 1990.
 95. **McAfee, R. P.**, and **McMillan, J.**, "Auctions and Bidding," *Journal of Economic Literature* 25:699-738, June 1987.
 96. **McCoombs, J.** and **Christianson, J.**, "Applying Competitive Bidding to Health Care," *Journal of Health Politics, Policy and Law* 12:703-22, Winter 1987.
 97. **McEvoy, G.**, (ed.), *American Hospital Formulary Service-Drug Information 1989* (Bethesda, MD: American Society of Hospital Pharmacists, 1989).
 98. **Means, R.**, **Olsen, N.**, **Krantz, S.**, et al., "Treatment of the Anemia of Rheumatoid Arthritis With Recombinant erythropoietin: Clinical and In Vitro Studies," *Arthritis and Rheumatism* 32(5):638-642, 1989.
 99. **Mendelson, P.**, Chief, End Stage Renal Disease Administrative Branch, Health Standards and Quality Bureau, Health Care Financing Administration, U.S. Department of Health and Human Services, Baltimore, MD, personal communication, Jan. 5, 1990.
 100. **Meyer, G.**, **Thum, J.**, and **Cada, E.**, et al., "Working Capacity is Increased Following Recombinant Human erythropoietin Treatment," *Kidney International* 34:525-528, 1988.
 - 100a. **Meyers, A. S.**, Executive Director, National Organization of Rare Disorders, Inc., New Fairfield, CT, "Statement," *The Orphan Drug Act, Drug Pricing, Competition and Reauthorization*, hearing before the Subcommittee on Health and the Environment, Committee on Energy and Commerce, House of Representatives, U.S. Congress, Washington, DC, Feb. 7, 1990.
 101. **Miller, C.B.**, **Jones, R.J.**, **Piantodosi, S.**, et al., "Decreased erythropoietin (EPO) Response Associated With the Anemia of Malignancy," Paper presented at American Society of Clinical Oncology Annual Meeting, San Francisco, CA, May 23, 1989.
 102. **Miyake, T.**, **Kung C.**, and **Goldwasser, E.**, "Purification of Human erythropoietin," *Journal of Biology and Chemistry* 252(15):5558-5563, August 1977.
 103. **National Medical Care, Inc.**, unpublished data, **Waltham, MA**, December 1989.
 104. **Neff, M.**, **Goldberg, J.**, **Slifkein, R.**, et al., "A Comparison of Androgens for Anemia in Patients on Hemodialysis," *New England Journal of Medicine* 304(15):871-875, 1981.
 105. **Neumayer, H.**, **Brockmoller, J.**, **Fritschka, E.**, et al., "Pharmacokinetics of Recombinant Human erythropoietin After Subcutaneous Administration and Long-Term Intravenous Treatment in Patients on Maintenance Hemodialysis," *erythropoietin: From Molecular Structure to Clinical Application*, C.A. **Baldamus**, et al. (eds.) (Switzerland: **Karger, Inc.**, 1989).
 - 105a. **Nissenson, A.R.**, "Recombinant Human Erythropoietin: Impact on Brain and Cognitive Function, Exercise Tolerance, Sexual Potency, and Quality of Life," *Seminars in Nephrology* 9(1), Supp 2:25-31, March 1989.
 106. **Nissenson, A.**, **Marsh, J.**, **Brown, W.**, et al., "Brain Function Improves in Chronic Hemodialysis Patients After Recombinant Erythro-

- poietin," *Kidney International*, Abstracts 35:257, 1989, as cited in A.R. Nissenson (105a).
107. Ogden, J., Director of Pharmacy Services, Marketing Center, U.S. Department of Veterans Affairs, Washington, DC, personal communication, October 1989.
 108. Ortho Pharmaceutical Corporation, Biotechnology Division. "Eprex: Treatment Program for Anemia in AIDS Patients," Raritan, NJ, May 1989.
 109. Otchin, N., Program Chief, Renal Diseases, Department of Veterans Affairs, Washington, DC, personal communication, March 1990.
 110. Pascual, J., Liano, F., Matesanz, P., "Recombinant Human erythropoietin Treatment in Patients on Maintenance Home Hemodialysis," *Lancet* 2(8655): 160, 1989.
 111. Pauly, M., "The Economics of Moral Hazard: Comment," *American Economic Review*; 531-37, June 1968.
 112. Pine, P., Statistician, Office of Research and Demonstrations, Program Studies Branch, Health Care Financing Administration, U.S. Department of Health and Human Services, Baltimore, MD, personal communication, January 1990.
 113. Raine, A., "Hypertension, Blood Viscosity, and Cardiovascular Morbidity in Renal Failure: Implications of erythropoietin Therapy," *Lancet* 1(8577):97-99, 1988.
 114. Raine, A., and Ledingham, J., "Cardiovascular Complications after Renal Transplantation," *Kidney Transplantation: Principles and Practice*, P. Morris (ed.) (London: Grunne and Stratton, 1984).
 115. Reekie, W. D., "Price and Quality Competition in the United States Drug Industry," *Journal of Industrial Economics* 26(3):223-37, 1978.
 116. Reissman, K., "Studies on the Mechanism of Erythropoetic Stimulation in Parabolic Rats During Hypoxia," *Blood* 5:372-380, 1950.
 117. Retterson, K., Product Manager, Amgen Company, Thousand Oaks, CA, personal communication, Sept. 4, 1989, October 1989, November 1989, December 1989, and March 20, 1990.
 118. Rettig, R., Study Director, Study of Medicare End Stage Renal Disease Program, Institute of Medicine, memorandum [on ESRD Dialysis Reimbursement Rate-Setting Process], Washington, DC, Dec. 27, 1989.
 119. Richman, D.D., Fischl M.A., Grieco, M.H., et al., "The Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex: A Double-Blind, Placebo-Controlled Trial," *New England Journal of Medicine* 317(4):192-197, 1987.
 120. Roberson, C., Associate Deputy Assistant Secretary for Depots, Marketing Center, U.S. Department of Veterans Affairs, Washington, DC, personal communication, October 1989.
 121. Rodgers, G., and Lessin, L., "Recombinant erythropoietin Improves the Anemia Associated with Gauchers Disease," *Blood* 73:8, 1989.
 122. Roxas, G., presentation to American Society of Nephrology meeting, Dallas, TX, Dec. 3, 1989.
 123. Sadler, J., President, Independent Dialysis Foundation, Inc., Baltimore, MD, personal communication, October 1989.
 124. Sagel, K., Program Analyst, End-Stage Renal Disease Program, Bureau of Data Management and Strategy, Health Care Financing Administration, U.S. Department of Health and Human Services, Baltimore, MD, letter to U.S. Congress, Office of Technology Assessment, Mar. 9, 1990.
 125. Schieber, G.S., and Poullier, J., "Overview of International Comparisons of Health Care Expenditures," *Health Care Financing Review*, 1989 Annual Supplement:1-7, 1989.
 126. Schumaker, B., Director, Division of Dialysis and Transplant Payment Policy, Bureau of Policy Development, Health Care Financing Administration, U.S. Department of Health and Human Services, Baltimore, MD, personal communication, Sept. 1, 1989 and Feb. 4, 1990.
 127. Scrip World Pharmaceutical News, "Erythropoietin in West Germany," *Scrip World Pharmaceutical News* 1381:1, Jan. 27, 1989.
 128. Shankerman, M.A., "Common Costs in Pharmaceutical Research and Development: Implications for Direct Price Regulations," *Impact of Public Policy on Drug Innovation and Pricing*, S.A. Mitchell (ed.), Proceedings of the Third Seminar on Pharmaceutical Public Policy Issues, 1976.

-
129. Simmons, L., Assistant Inspector General for Health Care Financing Audits, Office of the Inspector General, U.S. Department of Health and Human Services, Baltimore, MD, personal communication, Aug. 27, 1989.
 130. Sinai-Trieman, L., Salusky, I., and Fine, R., "Use of Subcutaneous Recombinant Human erythropoietin in Children Undergoing Continuous Cycling Peritoneal Dialysis," *Journal of Pediatrics* 114(4):530-534, 1989.
 131. Sobota, J., "Recombinant Human Erythropoietin in Patients With Anemia due to End-Stage Renal Disease," *Contributions in Nephrology* 76:166-178, 1989.
 132. Sobota, J., Executive Vice President, Chugai-Upjohn, Rosemont, IL, personal communication, Feb. 8, 1990.
 - 132a. Sobota, J. T., "erythropoietin Treatment of End-Stage Renal Disease: North American and Japanese Experience," *Erythropoietin in Clinical Practice: An International Perspective*, M. Garnick, (ed.) (New York: Marcel Dekker, in press, 1990).
 133. Spivak, J., Bender B., Quinn, T., "Hematologic Abnormalities in the Acquired Immunodeficiency Syndrome," *American Journal of Medicine* 77: 224-8, 1984.
 134. Steven, J.M., Hughs, R.T., Oliver, D.D., et al, "Subcutaneous Recombinant Human Erythropoietin in Patients on Continuous Ambulatory Peritoneal Dialysis," *Dialysis and Transplantation* 3:33(A), 1988.
 135. Stauffer, T. R., "Profitability Measures in the Pharmaceutical Industry," *Drug Development and Marketing*, R.B. Helms (ed.) (Washington, DC: American Enterprise Institute, 1975).
 136. Stipp, D., "Genetics Institute, Japanese Firm Seek Injunction Against Amgen in Patent Case," *Wall Street Journal*, February 1990.
 137. Stohlman, F., Rath, C., Rose, J., "Evidence for Humoral Regulation of Erythropoiesis: Studies on a Patient with Polycythemia Secondary to Regional Hypoxia," *Blood* 9:721-33, 1954.
 138. Styrsky, D., Chief, Pharmaceutical Products Division, Marketing Center, Department of Veterans Affairs, "Statement," hearing before the Special Committee on Aging, Senate, U.S. Congress, Washington, DC, July 13, 1989.
 139. Styrski, D., Chief, Pharmaceutical Division, Marketing Center, U.S. Department of Veterans Affairs, Hines, IL, personal communication, January 1990.
 140. Teehan, B., Sigler, M., Brown, J., et al., "Hematologic and Physiologic Studies During Correction of Anemia with Recombinant Human erythropoietin in Predialysis Patients," *Transplantation Proceedings*, 21(6):63-66, 1989.
 141. Toy, P., Strauss, R., Stehling, C., et al., "Predeposited Autologous Blood for Elective Surgery: A National Multicenter Study," *New England Journal of Medicine* 316(9):517-520, 1987.
 142. Turner, W., Pharmacist Reviewer, Office of Orphan Products Development, Food and Drug Administration, U.S. Department of Health and Human Services, Rockville, MD, personal communication, March 1990 and April 9, 1990.
 143. U.S. Congress, Office of Technology Assessment, *Assessing the Efficacy and Safety of Medical Technologies, OTA-H-75* (Washington DC: U.S. Government Printing Office, September 1978).
 144. U.S. Congress, Office of Technology Assessment, *Medical Technology Under Proposals To Increase Competition in Health Care, OTA-H-190* (Washington, DC: U.S. Government Printing Office, October 1982).
 145. U.S. Congress, Office of Technology Assessment, *Payment for Physician Services: Strategies for Medicare, OTA-H-294* (Washington, DC: U.S. Government Printing Office, February 1986).
 146. U.S. Congress, Office of Technology Assessment, *Life Sustaining Technologies and the Elderly, OTA-BA-306* (Washington, DC: U.S. Government Printing Office, July 1987).
 147. U.S. Congress, Office of Technology Assessment, *The Quality of Medical Care: Information for Consumers, OTA-H-386* (Washington, DC: U.S. Government Printing Office, June 1988).
 148. U.S. Congress, Office of Technology Assessment, *New Developments in Biotechnology: U.S. Investment in Biotechnology, OTA-BA-360* (Washington, DC: U.S. Government Printing Office, July 1988).

149. U.S. Congress, Office of Technology Assessment, New *Developments in Biotechnology Patenting Life - Special Report, OTA-BA-370* (Washington, DC: U.S. Government Printing Office, April 1989).
150. U.S. Department of Health and Human Services, Health Care Financing Administration, "Payment for Immunosuppressive Drugs Furnished to Transplant Patients," Section 5249, *Medicare Contractors Manual* (Baltimore, MD: February 1985).
151. U.S. Department of Health and Human Services, Health Care Financing Administration, "Reimbursement for ESRD Services and Supplies", *Medicare Provider Reimbursement Manual*, Transmittal No. 6 (Baltimore, MD: July 1986).
152. U.S. Department of Health and Human Services, Health Care Financing Administration, *National Kidney Dialysis and Kidney Transplantation Study* (Baltimore, MD, October 1986).
153. U.S. Department of Health and Human Services, Health Care Financing Administration, "Part 3-Claims Process," *Medicare Carriers Manual*, Transmittal 1177 (Baltimore, MD: February 1987).
154. U.S. Department of Health and Human Services, Health Care Finance Administration, "Part 1-Chapter 27: Reimbursement for ESRD Services and Transplant Services," *Medicare Provider Reimbursement Manual, HCFA Pub. 15-1-27* (Baltimore, MD: July, 1989).
155. U.S. Department of Health and Human Services, Health Care Financing Administration, "Part 3- Claims Process," *Medicare Carriers Manual, HCFA Pub. 14-3* (Baltimore, MD: November 1989).
156. U.S. Department of Health and Human Services, Health Care Financing Administration, *End Stage Renal Disease Program Quarterly Statistical Summary* (Baltimore, MD: Nov. 9, 1989).
157. U.S. Department of Health and Human Services, Health Care Financing Administration, *End Stage Renal Disease, 1987*, (Baltimore, MD: December 1989).
158. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Infectious Diseases, Division of HIV/AIDS, *HIV/AIDS Surveillance Report* (Atlanta, GA: February 1990).
159. U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration Blood Products Advisory Committee, **Rockville**, MD, May 11, 1989.
160. U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration. "Summary Basis of Approval for Epoetin **Alfa**," ELA #87-0535, PLA #87-0536, Washington, DC, June 1989.
161. U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, Office of Orphan Products Development, "Supplement to List of Orphan Drug Designations: Jan. 1, 1989-Aug. 1, 1989," **Rockville**, MD, September 1989.
162. U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, "HHS News," **P90-5**, Jan. 16, 1990.
163. U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, "HHS News," March 2, 1990.
164. U.S. Department of Health and Human Services, Public Health Service, National Center for Health Statistics, "Detailed Diagnoses and Surgical Procedures for Patients Discharged From Short-Stay Hospitals," 13(82) DHHS Pub. No. (PHS) 85-1743, 1985.
165. U.S. International Trade Commission, *In the Matter of Recombinant Erythropoietin*, Investigation 337-TA-281. January 1989.
166. U.S. Securities and Exchange Commission, 10K Report for Amgen, Inc. for the fiscal year ending March 1988, Washington, DC, #88157399, June 29, 1988.
167. U.S. Senate Special Committee on Aging. "Prescription Drug Prices: Are We Getting our Money's Worth?" Serial No. 101-D, (Senate Print 101-49) Washington, DC, August 1989.
168. Wall Street Journal, "Makers of EPO Drug Ordered to Submit Cross-Licensing Pacts," *Wall Street Journal*, p. B2, March 15, 1990.
169. Watson, A., "Adverse Effects of Therapy for the Correction of Anemia in Hemodialysis Patients," *Seminars in Nephrology* 9(1):30-33, 1989.

-
170. Weston, J.F., "Pricing in the Pharmaceutical Industry," *Issues in Pharmaceutical Economics*, R.A. Chien (ed.) (Lexington, MA: D.C. Heath and Company, 1979).
171. Winearls, C., Forman, E., Woffen, P., "Recombinant Human erythropoietin Treatment in Patients on Maintenance Home Hemodialysis," *Lancet* 2(8662): 569,1989.
172. Winearls, C., Oliver, D., Pippard, M., et al., "Effect of Human erythropoietin Derived from Recombinant DNA on the Anemia of Patients Maintained on Chronic Hemodialysis," *Lancet* 2(8517):1175-1178, 1986.
173. Wolcott, D. L., Schweitzer, S., and Nissenson, A. R., "Recombinant erythropoietin Improves Cognitive Function and Quality of Life of Chronic Hemodialysis Patients," *Kidney International*, Abstracts 35:266, 1989 as cited in A.R.Nissenson (105a).
174. Zahn, R., Director of Marketing, Biotechnology Division, Ortho Pharmaceutical Company, Raritan, NJ, personal communication, December 1989, Jan. 10, 1990 and March 20,1990.
175. Zen, L.I., and Groopman, J.E., "Hematological Manifestations of the Human Immune Deficiency Virus @V)," *Seminars in Hematology* 25(3):208-218, 1988.